Abaloparatide may help prevent fractures in postmenopausal women with osteoporosis

The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail